Nail disease and dactylitis influence treatment response in patients receiving etanercept or methotrexate

Key clinical point: The presence of dactylitis and nail disease were associated with improved outcomes in patients with early psoriatic arthritis (PsA) who received etanercept or methotrexate.

Major finding: The presence of both dactylitis and nail disease at baseline were significantly associated with the achievement of minimal disease activity (DA; odds ratio [OR] 1.4; P  =  .0457, and OR 1.8; P  =  .0233, respectively), PsA DA Score (PASDAS) of  low DA (OR 1.8; P  =  .0014, and OR 1.8; P  =  .0168, respectively) responses, and greater reductions in PASDAS scores at week 24 (estimate –3.8; P  =  .0155, and estimate –0.7; P  =  .0005, respectively).

Study details: Findings are from a post hoc analysis of the phase 3 SEAM-PsA trial including 851 biologic/methotrexate-naive patients with active PsA who were randomly assigned to receive methotrexate monotherapy, etanercept monotherapy, or methotrexate+etanercept combination therapy.

,

Disclosures: This study was funded by Immunex, a wholly owned subsidiary of Amgen. Three authors declared being employees or owning stocks in Amgen, and the other authors reported ties with several sources, including Amgen.

Source: Helliwell PS et al. Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: Comparison of treatment effects in the SEAM-PsA trial. RMD Open. 2022;8(2):e002366 (Jul 21). Doi: 10.1136/rmdopen-2022-002366